comparemela.com
Home
Live Updates
Long-term Benefit of Amivantamab Continues in Postplatinum NSCLC : comparemela.com
Long-term Benefit of Amivantamab Continues in Postplatinum NSCLC
Amivantamab elicited an objective response rate of 37% per investigator assessment, with a median duration of response of 12.5 months, according to long-term data from the CHRYSALIS trial.
Related Keywords
Denmark ,
Madrid ,
Spain ,
Copenhagen ,
Køavn ,
Pilar Garrido ,
European Lung Cancer Congress ,
Oncology Department Of University Hospital Ram ,
Universidad De Alcal ,
Thoracic Tumors Section ,
Medical Oncology Department ,
University Hospital Ram ,
Lung Cancer Congress ,
News ,
Articles ,
Lung Cancers ,
Publications ,
Nsclc ,
Nct02609776 ,
Chrysalis Trial ,
Rybrevant ,
Amivantamab ,
Non Small Cell Lung Cancer ,
comparemela.com © 2020. All Rights Reserved.